Cargando…

Molnupiravir for SARS-CoV-2 infection: Public health and policy implications

Detalles Bibliográficos
Autores principales:	Gray, Edward J., Nguyen-Van-Tam, Jonathan S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Author(s). Published by Elsevier Ltd on behalf of The British Infection Association. 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9786536/ https://www.ncbi.nlm.nih.gov/pubmed/36717180 http://dx.doi.org/10.1016/j.jinf.2022.10.040

Ejemplares similares

Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis
por: Kabinger, Florian, et al.
Publicado: (2021)

Decoding molnupiravir-induced mutagenesis in SARS-CoV-2
por: Menéndez-Arias, Luis
Publicado: (2021)

Combination therapy with nirmatrelvir and molnupiravir improves the survival of SARS-CoV-2 infected mice
por: Jeong, Ju Hwan, et al.
Publicado: (2022)

Molnupiravir—A Novel Oral Anti-SARS-CoV-2 Agent
por: Lee, Ching-Chi, et al.
Publicado: (2021)

Molnupiravir promotes SARS-CoV-2 mutagenesis via the RNA template
por: Gordon, Calvin J., et al.
Publicado: (2021)

Molnupiravir: A Versatile Prodrug against SARS-CoV-2 Variants
por: Teli, Divya, et al.
Publicado: (2023)

Safety and efficacy of molnupiravir in SARS‐CoV‐2‐infected patients: A real‐life experience
por: De Vito, Andrea, et al.
Publicado: (2022)

SARS-CoV-2 Omicron variant is highly sensitive to molnupiravir, nirmatrelvir, and the combination
por: Li, Pengfei, et al.
Publicado: (2022)

Molnupiravir inhibits SARS-CoV-2 variants including Omicron in the hamster model
por: Rosenke, Kyle, et al.
Publicado: (2022)

A molnupiravir-associated mutational signature in global SARS-CoV-2 genomes
por: Sanderson, Theo, et al.
Publicado: (2023)

Prevention of SARS-CoV-2 Infection Among Police Officers in Poland—Implications for Public Health Policies
por: Raciborski, Filip, et al.
Publicado: (2020)

Combined treatment of molnupiravir and favipiravir against SARS-CoV-2 infection: One + zero equals two?
por: Eloy, Philippine, et al.
Publicado: (2021)

Molnupiravir Inhibits Replication of the Emerging SARS-CoV-2 Variants of Concern in a Hamster Infection Model
por: Abdelnabi, Rana, et al.
Publicado: (2021)

Efficacy and safety of molnupiravir for the treatment of SARS-CoV-2 infection: a systematic review and meta-analysis
por: Malin, Jakob J, et al.
Publicado: (2023)

Combined molnupiravir-nirmatrelvir treatment improves the inhibitory effect on SARS-CoV-2 in macaques
por: Rosenke, Kyle, et al.
Publicado: (2023)

Combination Therapy with UV-4B and Molnupiravir Enhances SARS-CoV-2 Suppression
por: Franco, Evelyn J., et al.
Publicado: (2023)

Molnupiravir Does Not Induce Mutagenesis in Host Lung Cells during SARS-CoV-2 Treatment
por: Githaka, John Maringa
Publicado: (2022)

Real-world experience with molnupiravir during the period of SARS-CoV-2 Omicron variant dominance
por: Flisiak, Robert, et al.
Publicado: (2022)

Editorial: Rebound COVID-19 and Cessation of Antiviral Treatment for SARS-CoV-2 with Paxlovid and Molnupiravir
por: Parums, Dinah V.
Publicado: (2022)

153. Molnupiravir Exhibits a High Barrier to the Development of SARS-CoV-2 Resistance in vitro
por: Strizki, Julie, et al.
Publicado: (2022)

Evaluation of molnupiravir (EIDD-2801) efficacy against SARS-CoV-2 in the rhesus macaque model
por: Johnson, Dylan M., et al.
Publicado: (2023)

Combined Molnupiravir and Nirmatrelvir Treatment Improves the Inhibitory Effect on SARS-CoV-2 in Rhesus Macaques
por: Rosenke, Kyle, et al.
Publicado: (2022)

Comparing molnupiravir and nirmatrelvir/ritonavir efficacy and the effects on SARS-CoV-2 transmission in animal models
por: Cox, Robert M., et al.
Publicado: (2023)

Interactions of the Anti-SARS-CoV-2 Agents Molnupiravir and Nirmatrelvir/Paxlovid with Human Drug Transporters
por: Bakos, Éva, et al.
Publicado: (2023)

Policy Implications of an Approximate Linear Infection Model for SARS-CoV-2
por: McCarthy, John E., et al.
Publicado: (2020)

The combined treatment of Molnupiravir and Favipiravir results in a potentiation of antiviral efficacy in a SARS-CoV-2 hamster infection model
por: Abdelnabi, Rana, et al.
Publicado: (2021)

Molnupiravir combined with different repurposed drugs further inhibits SARS-CoV-2 infection in human nasal epithelium in vitro
por: Jonsdottir, Hulda R., et al.
Publicado: (2022)

Remdesivir, Molnupiravir and Nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concern
por: Vangeel, Laura, et al.
Publicado: (2022)

Inhibitors of dihydroorotate dehydrogenase cooperate with molnupiravir and N4-hydroxycytidine to suppress SARS-CoV-2 replication
por: Stegmann, Kim M., et al.
Publicado: (2022)

Correction: Real-world experience with molnupiravir during the period of SARS-CoV-2 Omicron variant dominance
por: Flisiak, Robert, et al.
Publicado: (2022)

Oxidative DNA Damage by N(4)-hydroxycytidine, a Metabolite of the SARS-CoV-2 Antiviral Molnupiravir
por: Kobayashi, Hatasu, et al.
Publicado: (2022)

Treating SARS-CoV-2 Omicron variant infection by molnupiravir for pandemic mitigation and living with the virus: a mathematical modeling study
por: Zheng, Qinyue, et al.
Publicado: (2023)

Successful Hematopoietic Stem Cell Transplantation from a Donor Sibling Infected with SARS-CoV-2 Using Molnupiravir Prophylaxis
por: Mandacı Şanlı, Neslihan, et al.
Publicado: (2023)

COVID-19 adaptive evolution during the pandemic – Implications of new SARS-CoV-2 variants on public health policies
por: van Oosterhout, Cock, et al.
Publicado: (2021)

Host range of SARS-CoV-2 and implications for public health
por: Santini, Joanne M, et al.
Publicado: (2020)

A Systematic Review of the Global Intervention for SARS-CoV-2 Combating: From Drugs Repurposing to Molnupiravir Approval
por: Ashour, Nada A, et al.
Publicado: (2022)

543. Molnupiravir Maintains Antiviral Activity Against SARS-CoV-2 Variants In Vitro and in Early Clinical Studies
por: Grobler, Jay, et al.
Publicado: (2021)

Characterisation of SARS-CoV-2 genomic variation in response to molnupiravir treatment in the AGILE Phase IIa clinical trial
por: Donovan-Banfield, I’ah, et al.
Publicado: (2022)

Real-World Effectiveness of SARS-CoV-2 Vaccine Booster in Hemodialysis Patients with COVID-19 Receiving Molnupiravir
por: Chen, Po-Chun, et al.
Publicado: (2023)

COVID-19 evolution during the pandemic – Implications of new SARS-CoV-2 variants on disease control and public health policies
por: van Oosterhout, Cock, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_3kr4ip3d8ti94hh1e131o8ueb2